2011-12-12 08:50 Aprea STOCKHOLM – December 12, 2011. Aprea AB today announces that the first patient has been dosed in a clinical Phase I/II-study of APR-246. The primary aim of the study is to evaluate safety and pharmacokinetics, but also to make an early assessment of effectiveness. Aprea is a Karolinska Development AB portfolio company. Other main owners are Industrifonden, Östersjöstiftelsen and Praktikerinvest.

2010-09-13 18:01 A+ Science Swedish Medtech makes A+ Science network partner

2010-02-20 11:29 A+ Science The Lancet, published february 18, contained an article with further findings from the ACCOMPLISH trial.

2009-12-14 14:30 A+ Science Biotech Sweden, one of the Nordic countries most read news media, elects an editorial council. The council aims to act as advisors and gather information about everything that affects the life science industry. Among the elected is A+ Science CEO, Agneta Franksson.